

CONDITIONS FOR SUBMITTING A COMMUNICATION:

The submission deadline for abstracts is January 7, 2027 at 11:59 p.m.

Your abstract must relate to an original work and must be written in **French**.

English language abstracts will not be evaluated.

REMINDER:

Author failing to present his or her oral or poster paper in the absence of an imperious reason will not be allowed to present a paper the following year. Oral presentations may only be given by an author who has signed the submitted abstract.

INSTRUCTIONS TO AUTHORS REGARDING THE WRITING OF ABSTRACTS:

1. Text size: 41 lines or 3000 characters excluding spaces. Max author number is 35.
2. Anonymity is required during the abstract review process. Please maintain anonymity by refraining from citing the team's previous work in the abstract or mentioning your institution in the abstract title.
3. INNs of drugs must be used in the abstracts, not trade names.
4. It is detrimental to split a work into several abstracts.
5. The text of the communication, regardless of the mode of presentation, may be published *in extenso* by the SFH.
6. **Encore abstracts are accepted and will be considered along with all other submitted papers.**